KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) announced that it will present at the 14th Annual Needham Healthcare Conference in New York CityNew York on April 14, 2015.

Herb Cross, Interim Chief Executive Officer and Chief Financial Officer of KaloBios, will provide an update on the company's KB004 (anti-EphA3 mAb) program to treat hematologic malignancies and with the potential to treat solid tumors. This program is currently in the Phase 2 expansion portion of its Phase 1/2 study, enrolling patients with myelodysplastic syndrome or myelofibrosis. KaloBios has completed a Phase 1 dose-escalating clinical trial in hematologic malignancies at multiple sites inthe United States and Australia, the results of which were presented in a poster presentation at the American Society of Hematology Annual Conference in December 2014.  

14th Annual Needham Healthcare Conference


Westin New York Grand Central Hotel


Tuesday, April 14, 2015


10:00 AM-10:40 AM U.S. Eastern Time (7:00 AM-7:40 AM U.S. Pacific Time)

Individuals may access a live audio webcast of the BIO & CEO Investor presentation by visiting the company's Events & Presentations page. A replay of the webcast will be available on this site for 90 days following the live event. (Original Source)

Shares of KaloBios closed last Thursday at $0.5101 . KBIO has a 1-year high of $2.66 and a 1-year low of $0.36. The stock's 50-day moving average is $0.54 and it's 200-day moving average is $1.21.

On the ratings front, Needham analyst Alan Carr reiterated a Hold rating on KBIO, In a report issued on January 7.

According to TipRanks.com, Carr has a total average return of 42.2%, a 71.8% success rate, and is ranked #5 out of 3568 analysts.

KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.